All In Biotech

Drug Trial Radar · NCT06464991

A Phase III Study of Eque-cel in Subjects With Len-refractory RRMM (FUMANBA-03)

A Phase III Randomized, Controlled Study of Equecabtagene Autoleucel Injection in Subjects With Lenalidomide-Refractory R/R Multiple Myeloma

Last checked: Nov 19, 2026Latest source record: Nov 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 260 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

260

Planned (sponsor's estimate)

Start

Mar 27, 2024

Primary completion

Aug 2027

Study completion Dec 2030

Sponsor

Sponsor type
Industry
First posted
Jun 18, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multicenter, randomized, controlled, open-label, phase III clinical study to evaluate the efficacy of Equecabtagene Autoleucel Injection versus standard therapy in subjects with lenalidomide-refractory relapsed/refractory multiple myeloma (RRMM) who have received 1-2 lines of prior therapy. Approximately 240 subjects from China and, in accordance with Japanese regulatory requirements, approximately 20 additional subjects from Japan are planned to be enrolled in this study, for a total of approximately 260 subjects.

Conditions

  • Multiple Myeloma

Interventions

  • Equecabtagene Autoleucel InjectionDrug

    dosage form: injection, dosage: 1.0×10\^6 CAR-T/kg, frequency: single dose.

  • DaratumumabDrug

    dosage form: injection or subcutaneous injection. For intravenous administration: dose level 16 mg/kg, 28 days/cycle for the DPd regimen * Cycle1-2: D1, D8, D15, D22; * Cycle3-6: D1, D15; * above Cycle7: D1; body weight should be recalculated on D1 of the current cycle if it differs from baseline by more than +/-10%. For subcutaneous administration: fixed dose of 1,800 mg. The formulation and route of administration (intravenous or subcutaneous) should be selected according to the clinical practice in the country where the study is conducted.

  • PomalidomideDrug

    dosage form:capsule. doseage form: capsule. dose level: 4mg/d. frequency: every cycle: D1-D21 for DPd regimen, D1-D14 for PVd regimen.

  • BortezomibDrug

    dosage form: subcutaneous injection. dose level: 1.3mg/m2. frequency: 21days/cycle for PVd regimen cycle 1-8: D1,D4, D8, D11; above cycle 9: D1, D8.

  • DexamethasoneDrug

    dosage form: oral or intravenus injection. dose level:20mg/d. frequency: for DPd: every cycle, D1, D2, D8, D9, D15, D16, D22, D23; for PVd: Cycle1-8:D1, D2, D4, D5, D8, D9, D11, D12; above Cycle 9: D1, D2, D8, D9.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Minimal Residual Disease (MRD)-negative complete response (CR) rate at 12 monthsTime frame: 12 months (+/-3 months) post-randomization
  2. Progression-Free Survival (PFS) as assessed by Independent Review Committee (IRC)Time frame: up to 5 years from randomization

Locations

41 sites in 2 countries. Site status is shown where the registry gives one.

  • Beijing Chao-Yang Hospital, Capital Medical University

    Beijing, China

  • Beijing GoBoard Boren Hospital

    Beijing, China

  • Fu Xing Hospital, Capital Medical University

    Beijing, China

  • Peking Union Medical College Hospital

    Beijing, China

  • Peking University First Hospital

    Beijing, China

  • Peking University Third Hospital

    Beijing, China

  • People's Hospital of Peking University

    Beijing, China

  • The first hospital of Jilin University

    Changchun, China

  • West China School of Medicine, West China Hospital of Sichuan University

    Chengdu, China

  • Xinqiao Hospital of AMU

    Chongqing, China

  • Nanfang Hospital, Southern Medical University

    Guangzhou, China

  • Sun Yat-sen University Cancer Centre

    Guangzhou, China

  • Zhujiang Hospital of Southern Medical University Guangdong

    Guangzhou, China

  • The First Affiliated Hospital, College of Medicine, Zhejiang University

    Hangzhou, China

  • The Second Affiliated Hospital,Zhejiang University School of Medicine

    Hangzhou, China

  • Qilu Hospital of Shangdong University

    Jinan, China

  • The First Affiliated Hospital of Nanchang University

    Nanchang, China

  • Affiliated Drum Tower Hospital, Medical School of Nanjing University

    Nanjing, China

  • Jiangsu Province Hospital

    Nanjing, China

  • The Affiliated People's Hospital of Ningbo University

    Ningbo, China

  • Ruijin Hospital, Shanghai Jiaotong University School of Medicine

    Shanghai, China

  • The First Affiliated Hospital of Soochow University

    Suzhou, China

  • Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences

    Tianjin, China

  • Tianjin Medical University General Hospital

    Tianjin, China

  • The First Affiliated Hospital of Wenzhou Medical University

    Wenzhou, China

  • Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology

    Wuhan, China

  • Union Hospital Affiliated to Tongji Medical College, Huazhong University of Science and Technology

    Wuhan, China

  • Henan Cancer Hospital Affilated Cancer Hospital of Zhengzhou University

    Zhengzhou, China

  • Kyushu University Hospital

    Fukuoka, Japan

  • Hiroshima Red Cross Hospital & Atomic-bomb Survivors Hospital

    Hiroshima, Japan

  • Hokkaido University Hospital

    Hokkaido, Japan

  • Hyogo Medical University Hospital

    Hyōgo, Japan

  • University Hospital, Kyoto Prefectural University of Medicine

    Kyoto, Japan

  • Nagoya City University Hospital

    Nagoya, Japan

  • Kindai University Hospital

    Osaka, Japan

  • The University of Osaka Hospital

    Osaka, Japan

  • Jichi Medical University Hospital

    Tochigi, Japan

  • Institute of Science Tokyo Hospital

    Tokyo, Japan

  • Japanese Red Cross Medical Center

    Tokyo, Japan

  • Nihon University Itabashi Hospital

    Tokyo, Japan

Showing 40 of 41 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.